Loading data for NGEN — first visit, this takes a few seconds.
NervGen Pharma Corp. (NGEN)
NasdaqCM: NGEN
· Real-Time Price · USD
2.25
-0.03 (-1.32%)
At close: Aug 31, 2026, 4:49 PM
The price, the headline numbers and the latest news, in one place.
NervGen Pharma Corp. (NGEN) Stock Price, Analysis & Data
-1.32% (1D)
No data available
| Bid | 2.29 |
| Market Cap | 243.54M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -61.96M |
| 0.69 | |
| -0.57 | |
| n/a | |
| -6.64 | |
| P/B (ttm) | 16.80 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 23, 2026 |
| Ask | 2.9 |
| Volume | 265,391 |
| Avg. Volume (20D) | 710,671 |
| Open | 2.27 |
| Previous Close | 2.28 |
| Day's Range | 2.16 - 2.29 |
| 52-Week Range | 1.58 - 6.30 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About NGEN
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical mo...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 3, 2019
Employees 9
Stock Exchange NasdaqCM
Ticker Symbol NGEN
Website https://nervgen.com
Financial Performance
In 2025, NervGen Pharma's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -44.12M, an increase of 81.93%.
Financial StatementsEarnings Surprise
NervGen Pharma has released their quarterly earnings on Aug 13, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.23 misses estimates by -0.16, with -475.00% YoY decline.
NervGen Pharma Corp. is scheduled to release its earnings on Nov 23, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
